$SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Jeffrey T. Finer
CEO
75
Employees
$37.75
Current Price
$1.20B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $126,077.72 | 3,333 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 6 | $64,793,497.61 | 1,524,667 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 10 | $65,120,621.88 | 1,534,178 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Long Daniel D. SVP, Drug Discovery | Sale | 3,333 | $37.83 | $126,077.72 | View Details |
| Aug 12, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | 746,500 | $42.50 | $31,726,250.00 | View Details |
| Aug 12, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | 746,500 | $42.50 | $31,726,250.00 | View Details |
| Aug 11, 2026 | Bhatt Elizabeth President and COO | Sale | 25,000 | $44.00 | $1,100,000.00 | View Details |
| Aug 3, 2026 | Long Daniel D. SVP, Drug Discovery | Sale | 1,000 | $33.98 | $33,975.60 | View Details |
| Aug 3, 2026 | Long Daniel D. SVP, Drug Discovery | Sale | 2,334 | $34.68 | $80,944.29 | View Details |
| Jul 15, 2026 | Bhatt Elizabeth President and COO | Sale | 4,000 | $33.99 | $135,974.00 | View Details |
| Jul 1, 2026 | Long Daniel D. SVP, Drug Discovery | Sale | 2,100 | $34.10 | $71,602.44 | View Details |
| Jul 1, 2026 | Long Daniel D. SVP, Drug Discovery | Sale | 1,233 | $34.81 | $42,925.79 | View Details |
| Jun 29, 2026 | Shaikhly Samira Chief People Officer | Sale | 2,178 | $35.18 | $76,622.04 | View Details |
15 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.